A meta‐analysis in 2022 reported that anti‐PD‐(L)1 therapy with or without chemotherapy achieved more prolonged survival than mono‐chemotherapy for KRAS‐mutant NSCLC (https://doi.org/10.1007/s00262‐021‐03031‐1). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.